🇺🇸 FDA
Patent

US 6995261

4-pyridazinecarboxamides and esters as interleukin-1β converting enzyme inhibitors

expired A61PA61P19/02A61P29/00

Quick answer

US patent 6995261 (4-pyridazinecarboxamides and esters as interleukin-1β converting enzyme inhibitors) held by Vertex Pharmaceuticals Incorporated expires Mon Feb 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Feb 07 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P19/02, A61P29/00, A61P35/00, A61P43/00